6.1 The Four Pillars of GDMT: ARNI/ACEi/ARB, Beta-Blockers, MRA, and SGLT2i

Foundational Architecture of GDMT in HFrEF (The Four Pillars)

Pharmacotherapy for heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction [LVEF] ≤40%) has undergone a fundamental paradigm shift. Historical management relied on a slow, sequential titration approach where single agents were added and titrated to target doses over months before introducing the next class. Modern practice, codified in the ACC/AHA/HFSA Heart Failure Guidelines, mandates the prompt implementation of four foundational pharmacologic pillars:

1. Renin-Angiotensin System Inhibition: Angiotensin Receptor-Neprilysin Inhibitor (ARNI preferred), Angiotensin-Converting Enzyme Inhibitor (ACEi), or Angiotensin Receptor Blocker (ARB)
2. Evidence-Based Beta-Blockers: Carvedilol, Metoprolol Succinate extended-release, or Bisoprolol
3. Mineralocorticoid Receptor Antagonists (MRA): Spironolactone or Eplerenone
4. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i): Dapagliflozin or Empagliflozin

When deployed collectively at target or maximally tolerated doses, this "quadruple therapy" modifies ventricular remodeling, decreases sudden cardiac death, and is estimated from trial data to lower 2-year all-cause mortality by about 73% versus no treatment; a cross-trial analysis projected 1.4 to 6.3 additional years of life depending on age.

---

Pillar 1: Renin-Angiotensin System Inhibition (ARNI / ACEi / ARB)

Neurohormonal hyperactivation of the renin-angiotensin-aldosterone system (RAAS) causes maladaptive systemic vasoconstriction, sodium and water retention, myocyte hypertrophy, and interstitial fibrosis. Inhibiting this cascade halts and partially reverses adverse left ventricular remodeling.

                  ┌───────────────────────────────────────────────────┐
                  │             Sacubitril / Valsartan (ARNI)         │
                  └─────────┬───────────────────────────────┬─────────┘
                            │                               │
                            ▼                               ▼
               ┌─────────────────────────┐     ┌─────────────────────────┐
               │   Sacubitril (Prodrug)  │     │        Valsartan        │
               │            │            │     │            │            │
               │            ▼            │     │            ▼            │
               │    LBQ657 Active Form   │     │    Blocks AT1 Receptor  │
               │            │            │     │            │            │
               │            ▼            │     │            ▼            │
               │    Inhibits Neprilysin  │     │   Blocks Angiotensin II │
               └────────────┬────────────┘     └────────────┬────────────┘
                            │                               │
                            ▼                               ▼
               ┌─────────────────────────┐     ┌─────────────────────────┐
               │ ↑ Active Natriuretic    │     │ ↓ Vasoconstriction      │
               │   Peptides (ANP, BNP)   │     │ ↓ Aldosterone & Fibrosis│
               │ ↑ Vasodilation & Diuresis│     │ ↓ Sodium Retention      │
               └─────────────────────────┘     └─────────────────────────┘

Angiotensin Receptor-Neprilysin Inhibitors (ARNI)

Sacubitril/valsartan combines an AT1 receptor blocker (valsartan) with a neprilysin inhibitor prodrug (sacubitril), which is hydrolyzed by esterases to its active moiety, LBQ657.

• Mechanism: Neprilysin is an endopeptidase that breaks down endogenous vasoactive peptides, including atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), bradykinin, adrenomedullin, and substance P. By inhibiting neprilysin, sacubitril augments circulating natriuretic peptides, increasing cyclic guanosine monophosphate (cGMP), which induces vasodilation, natriuresis, and antifibrotic signaling. Concurrently, valsartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone synthesis while mitigating the unopposed angiotensin II accumulation caused by neprilysin inhibition.
• Landmark Evidence (PARADIGM-HF): Sacubitril/valsartan was evaluated against enalapril 10 mg twice daily in 8,442 patients with chronic HFrEF (LVEF ≤40%, later amended to ≤35%). The trial was stopped early for overwhelming efficacy: sacubitril/valsartan demonstrated a 20% relative risk reduction (RRR) in the primary composite endpoint of cardiovascular death or HF hospitalization (p < 0.001), a 16% reduction in all-cause mortality, and a 20% reduction in sudden cardiac death.
• Guideline Status: Class 1 (Level of Evidence A) in NYHA class II–III HFrEF to reduce morbidity and mortality, and patients who tolerate an ACEi or ARB should be switched to an ARNI (Class 1).
• The Mandatory 36-Hour Washout Period: Both ACE and neprilysin degrade bradykinin. Concurrent administration of an ACE inhibitor and an ARNI produces synergistic accumulation of bradykinin, precipitating severe, life-threatening angioedema. Therefore, when switching from an ACE inhibitor to sacubitril/valsartan, clinicians must enforce a strict, mandatory 36-hour washout period from the last dose of the ACE inhibitor before administering the first dose of ARNI. Critical Note: A washout period is not required when switching from an ARB to an ARNI, because ARBs do not inhibit bradykinin degradation.
• Absolute Contraindications: History of angioedema related to prior ACEi or ARB therapy, or hereditary angioedema; concomitant use with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes; pregnancy (teratogenic black box warning).
• Dosing & Titration: Initial starting dose is 24/26 mg (sacubitril 24 mg / valsartan 26 mg) orally twice daily for patients naive to ACEi/ARB or previously on low doses, or 49/51 mg twice daily for patients on standard-to-high doses of ACEi/ARB. Titrate every 2 to 4 weeks toward the target maintenance dose of 97/103 mg twice daily.

ACE Inhibitors and ARBs

• ACE Inhibitors (Enalapril, Lisinopril, Ramipril): Block the conversion of angiotensin I to angiotensin II and retard bradykinin degradation. Landmark trials (CONSENSUS, SOLVD) established a 16% to 27% reduction in mortality. Reserved for patients with financial or insurance barriers to ARNI therapy.
• Angiotensin Receptor Blockers (Candesartan, Valsartan, Losartan): Selectively block AT1 receptors without affecting bradykinin metabolism. Recommended for patients intolerant of ACE inhibitors due to intractable bradykinin-mediated dry cough or when ARNI therapy is unavailable.

Laboratory Monitoring and Hemodynamic Parameters

Baseline serum potassium and renal function (serum creatinine and eGFR) must be assessed prior to initiation and repeated within 1 to 2 weeks following initiation or dose escalation.

• The Expected Creatinine Elevation: A transient increase in serum creatinine of up to 30% above baseline (with an accompanying modest drop in eGFR) is an expected hemodynamic response reflecting reduced intraglomerular capillary pressure as post-glomerular efferent arterioles dilate. Unless accompanied by severe hyperkalemia (K+ >5.5 mEq/L) or overt volume depletion, this rise does not indicate acute tubular necrosis and is not a reason to stop therapy.
• Biomarker Caveat: As covered in biomarker diagnostics, active BNP is degraded by neprilysin; therefore, circulating BNP rises pharmacologically on ARNI therapy and cannot be used to gauge clinical volume. NT-proBNP is not degraded by neprilysin and is the preferred natriuretic peptide for monitoring patients on sacubitril/valsartan.

---

Pillar 2: Evidence-Based Beta-Blockers

Chronic sympathetic nervous system (SNS) hyperactivity with sustained catecholamine stimulation causes down-regulation and desensitization of cardiac beta-1 adrenergic receptors, myocyte calcium overload, interstitial fibrosis, and fatal ventricular arrhythmias. Beta-blockers reverse this remodeling, restore beta-receptor density, reduce heart rate, and prolong diastolic coronary perfusion time.

The Three Guideline-Approved Beta-Blockers

Only three specific beta-blockers have demonstrated substantial mortality reduction in large randomized controlled trials in HFrEF. The Certified Heart Failure Nurse (CHFN) must recognize that beta-blocker efficacy in HFrEF is an agent-specific property, not a class effect.

[!WARNING] Critical Exam Trap: Metoprolol Succinate extended-release (Toprol-XL) vs. Metoprolol Tartrate (Lopressor). Metoprolol succinate is a once-daily, sustained-release formulation proven to reduce mortality in HFrEF. Metoprolol tartrate is an immediate-release formulation dosed two to three times daily, approved for hypertension, angina, and post-MI management, but has never demonstrated mortality reduction in HFrEF. Prescribing or continuing metoprolol tartrate in HFrEF is an egregious clinical error.

Initiation Rules and Clinical Management

1. Clinical Euvolemia Requirement: Beta-blockers must never be initiated or uptitrated in patients with overt volume overload, acute decompensation, or inotrope dependence. Acute beta-blockade temporarily suppresses contractility; initiating therapy during active pulmonary edema can precipitate cardiogenic shock.
2. "Start Low, Go Slow": Begin at tiny starting doses (carvedilol 3.125 mg BID, metoprolol succinate 12.5 to 25 mg daily, bisoprolol 1.25 mg daily). Titrate upward slowly every 2 weeks, assessing blood pressure, heart rate (target resting HR 55 to 65 bpm), and volume status at each step.
3. Managing Transient Adverse Effects:
   • Transient Fluid Retention: If the patient develops mild weight gain or peripheral edema during titration, do not stop the beta-blocker. Temporarily increase the oral loop diuretic dose until euvolemia is restored, then continue beta-blocker titration.
   • Transient Fatigue: Warn patients that mild fatigue is common during the first 1 to 2 weeks after a dose change and typically resolves spontaneously as receptors adapt.
   • Bradycardia: If asymptomatic bradycardia occurs (HR 50–55 bpm), no action is required. If symptomatic bradycardia develops, evaluate and reduce concurrent non-essential nodal agents (e.g., digoxin) before lowering the beta-blocker.

---

Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs)

Aldosterone acts on mineralocorticoid receptors in the distal nephron to promote sodium and water reabsorption in exchange for potassium and hydrogen ion excretion. In heart failure, pathologically elevated aldosterone levels drive interstitial myocardial collagen deposition, microvascular stiffening, ventricular hypertrophy, and baroreceptor dysfunction. The phenomenon of "aldosterone breakthrough" occurs in up to 50% of patients on chronic ACEi/ARB therapy, wherein circulating aldosterone levels rebound within weeks despite upstream RAAS blockade, necessitating direct mineralocorticoid receptor antagonism.

Approved Agents and Landmark Trials

• Spironolactone: Non-selective mineralocorticoid receptor antagonist. In the RALES trial (Randomized Aldactone Evaluation Study), adding spironolactone (mean dose 26 mg daily) to standard therapy in severe HFrEF (NYHA Class III-IV, LVEF ≤35%) reduced all-cause mortality by 30% (p < 0.001) and reduced HF hospitalizations by 35%.
• Eplerenone: Selective mineralocorticoid receptor antagonist. In EMPHASIS-HF (NYHA Class II HFrEF), eplerenone produced a 37% reduction in CV death or HF hospitalization; in EPHESUS (post-MI LV dysfunction with HF or diabetes), it reduced all-cause mortality by 15%.

Mandatory Initiation Thresholds & Monitoring

MRAs carry a significant risk of life-threatening hyperkalemia if prescribed indiscriminately. Guidelines mandate the following baseline criteria before initiating spironolactone or eplerenone:

• Serum Potassium: Must be ≤ 5.0 mEq/L (if K+ >5.0 mEq/L, initiation is strictly contraindicated).
• Estimated GFR: Must be ≥ 30 mL/min/1.73m² (or serum creatinine ≤2.5 mg/dL in men, ≤2.0 mg/dL in women).
• Mandatory Laboratory Follow-up: Check serum potassium and renal function at 1 week, 4 weeks, 3 months, and every 3 to 6 months thereafter, as well as 1 week after any dose modification.
• Dosing: Spironolactone starting dose is 12.5 to 25 mg once daily (target 25 to 50 mg daily). Eplerenone starting dose is 25 mg once daily (target 50 mg daily).

Endocrine Side Effects: Non-Selective vs. Selective

Spironolactone has structural homology to progesterone and testosterone, causing non-specific binding to androgen and progesterone receptors. This induces endocrine side effects in up to 10% of male patients, manifesting as painful gynecomastia, mastodynia (breast tenderness), erectile dysfunction, and menstrual irregularities in premenopausal women.

• Clinical Action: If a male patient on spironolactone develops painful gynecomastia, switch immediately to eplerenone, which has high selectivity for the mineralocorticoid receptor with negligible (<0.1%) affinity for androgen receptors, resolving the symptoms while preserving mortality benefit.

---

Pillar 4: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

Originally developed as oral hypoglycemic agents for Type 2 diabetes mellitus, SGLT2 inhibitors represent one of the most transformative advances in heart failure therapeutics. In the proximal convoluted tubule of the kidney, SGLT2 inhibitors block sodium and glucose reabsorption, promoting glucosuria and natriuresis.

              ┌────────────────────────────────────────────────────────┐
              │            SGLT2 Inhibitors (Dapa / Empa)              │
              └───────────────────────────┬────────────────────────────┘
                                          │
         ┌────────────────────────────────┼────────────────────────────────┐
         ▼                                ▼                                ▼
┌─────────────────┐              ┌─────────────────┐              ┌─────────────────┐
│Renal Effects    │              │Cardiovascular   │              │Metabolic        │
│• Natriuresis &  │              │  Hemodynamics   │              │  Energetics     │
│  osmotic diuresis│             │• ↓ Preload &    │              │• Shifting fuel  │
│• Restores       │              │  afterload      │              │  to ketones     │
│  tubuloglomerular│             │• ↓ Interstitial │              │• Enhanced       │
│  feedback       │              │  edema          │              │  mitochondrial  │
│• Reduces        │              │• Reverses LV    │              │  ATP production │
│  intraglomerular│              │  remodeling     │              │• Improved       │
│  pressure       │              │• Neutral SNS &  │              │  myocardial     │
│• Preserves eGFR │              │  heart rate     │              │  efficiency     │
└─────────────────┘              └─────────────────┘              └─────────────────┘

Landmark Evidence: DAPA-HF and EMPEROR-Reduced

• DAPA-HF (Dapagliflozin): Evaluated dapagliflozin 10 mg daily vs. placebo in 4,744 patients with HFrEF (LVEF ≤40%). Demonstrated a 26% relative risk reduction in CV death or worsening HF events (p < 0.0001). Remarkably, outcomes were identical in patients without diabetes as in those with diabetes.
• EMPEROR-Reduced (Empagliflozin): Evaluated empagliflozin 10 mg daily vs. placebo in 3,730 patients with HFrEF (LVEF ≤40%). Demonstrated a 25% relative risk reduction in CV death or HF hospitalization (p < 0.001), accompanied by a slower rate of eGFR decline.

Distinct Pharmacologic Properties

• Glycemic Independence: SGLT2 inhibitors improve cardiovascular outcomes and survival regardless of the presence or absence of Type 2 diabetes. Hypoglycemia does not occur in non-diabetic patients.
• Flat, Fixed Dosing: Both dapagliflozin and empagliflozin are administered at a fixed dose of 10 mg orally once daily. There is no dose titration required, eliminating the complex dose-escalation barriers seen with other GDMT classes.
• eGFR Initiation Thresholds: Approved for HFrEF initiation down to an eGFR of 20 mL/min/1.73m² (empagliflozin) or 25 mL/min/1.73m² (dapagliflozin). Once initiated, therapy can generally be continued until dialysis.

Key Patient Education and Nursing Safeguards

1. Genital Mycotic Infections: Glucosuria increases the risk of vulvovaginal candidiasis and fungal balanitis. Educate patients on meticulous perineal hygiene and hydration.
2. Volume Depletion: Mild osmotic diuresis (300–400 mL/day) may compound loop diuretic effects. In euvolemic patients with borderline low blood pressure, clinicians often reduce baseline loop diuretic doses by 20% to 50% upon SGLT2i initiation.
3. Euglycemic Diabetic Ketoacidosis (euDKA): In patients with diabetes, physiologic stress (infection, major surgery, dehydration, prolonged fasting) can precipitate ketoacidosis with normal or minimally elevated blood glucose (<250 mg/dL). Instruct patients to hold SGLT2 inhibitors at least 3 days before scheduled surgery (per labeling) and during acute critical illness.

---

Quadruple GDMT Pillars at a Glance

---

Contemporary Rapid Sequencing Strategy

Modern heart failure practice has abandoned the historical paradigm of titrating one drug to maximum dose before starting another. Benefits from each pillar emerge within weeks of initiation (SGLT2 inhibitor benefit appears within about the first month), so delaying a pillar forfeits early benefit.

                          RAPID QUADRUPLE GDMT SEQUENCING
                 ┌──────────────────────────────────────────────┐
                 │ Diagnosis of HFrEF (LVEF ≤40%) in Hospital/Clinic │
                 └──────────────────────┬───────────────────────┘
                                        │
                                        ▼
                 ┌──────────────────────────────────────────────┐
                 │ Day 1–7: Step 1                              │
                 │ • SGLT2i (10 mg daily flat dose)             │
                 │ • Beta-Blocker (low dose, once euvolemic)     │
                 └──────────────────────┬───────────────────────┘
                                        │
                                        ▼
                 ┌──────────────────────────────────────────────┐
                 │ Day 7–14: Step 2                             │
                 │ • ARNI (initiate low-dose; enforce 36h       │
                 │   washout if on prior ACEi)                  │
                 │ • MRA (initiate if K+ ≤5.0, eGFR ≥30)        │
                 └──────────────────────┬───────────────────────┘
                                        │
                                        ▼
                 ┌──────────────────────────────────────────────┐
                 │ Week 2 to 6: Titration Phase                 │
                 │ • Uptitrate Beta-Blocker every 2 weeks       │
                 │ • Uptitrate ARNI every 2 to 4 weeks          │
                 │ • Monitor K+ and Cr at 1-2 weeks post-change │
                 │ • Target: All 4 Pillars Active by Week 4–6!  │
                 └──────────────────────────────────────────────┘

• Simultaneous or Near-Simultaneous Initiation: Low doses of all four pillars should be established within 4 to 6 weeks of initial diagnosis.
• SGLT2i and Beta-Blocker First: SGLT2 inhibitors carry no blood pressure or titration hurdles and reduce early readmissions. Beta-blockers provide early anti-arrhythmic protection.
• ARNI and MRA Synergy: Combining an ARNI with an MRA provides complementary RAAS suppression. The mild natriuretic/kaliuretic profile of neprilysin inhibition may actually attenuate the hyperkalemia risk associated with MRAs.

---

Clinical Case Scenario: Rapid GDMT Optimization

A 58-year-old female is evaluated in the outpatient heart failure clinic two weeks following an admission for acute decompensated non-ischemic cardiomyopathy. Her discharge echocardiogram demonstrated an LVEF of 28% with global LV hypokinesis. During hospitalization, she was decongested with intravenous loop diuretics and discharged on enalapril 5 mg twice daily, metoprolol succinate 25 mg once daily, and oral furosemide 20 mg daily.

• Vital Signs & Exam: BP 118/74 mmHg, HR 68 bpm (regular sinus rhythm), weight stable, lungs clear, JVP 5 cm H₂O, no peripheral edema. Euvolemic.
• Labs: Serum sodium 139 mEq/L, potassium 4.4 mEq/L, BUN 18 mg/dL, creatinine 1.0 mg/dL (eGFR 68 mL/min/1.73m²), NT-proBNP 1,120 pg/mL. Hemoglobin A1c is 5.4% (non-diabetic).
• Clinical Decision & Strategy:
  1. The nurse identifies that the patient is missing two critical pillars (MRA and SGLT2i) and should be transitioned from an ACEi to an ARNI for superior mortality reduction.
  2. Step 1 (ARNI Transition): Instruct the patient to stop enalapril immediately. Schedule the first dose of sacubitril/valsartan 24/26 mg BID to begin exactly 36 hours after the final enalapril dose to prevent angioedema.
  3. Step 2 (Add Pillar 3 - MRA): Because baseline potassium is ≤5.0 mEq/L (4.4 mEq/L) and eGFR is ≥30 mL/min/1.73m² (68 mL/min), start spironolactone 25 mg daily.
  4. Step 3 (Add Pillar 4 - SGLT2i): Although the patient is not diabetic, start empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily. No titration is required.
  5. Step 4 (Follow-up): Schedule laboratory testing (K+ and Cr) in 7 to 14 days, and plan to uptitrate metoprolol succinate to 50 mg daily at the 2-week follow-up.

---

CHFN Exam Traps & Clinical Pearls

[!WARNING] Exam Trap: Watch out for questions offering metoprolol tartrate for HFrEF! Only three beta-blockers reduce mortality in HFrEF: metoprolol succinate, carvedilol, and bisoprolol. Metoprolol tartrate has never been shown to reduce mortality in HFrEF.

[!IMPORTANT] Clinical Pearl: Always verify the 36-hour washout when switching from an ACE inhibitor to an ARNI. If switching from an ARB (e.g., losartan) to an ARNI, no washout is needed—the ARNI can be started when the next ARB dose was due.

[!TIP] Clinical Pearl: Do not reflexively stop an ARNI or ACEi for a mild serum creatinine increase. An elevation of up to 30% above baseline is expected due to intraglomerular hemodynamics and reflects therapeutic efferent arteriolar vasodilation.